Poxviral-based vaccine elicits immunologic responses in prostate cancer patients

Prostvac is a poxviral-based vaccine designed to target prostate-specific antigen (PSA) in prostate cancer patients. Recently, the potential toxicity and immunological impact of this immunotherapy were reviewed in the context of new clinical data. Our findings suggest that Prostvac is safe and elici...

Descripción completa

Detalles Bibliográficos
Autores principales: Madan, Ravi A, Heery, Christopher R, Gulley, James L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2014
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4091323/
https://www.ncbi.nlm.nih.gov/pubmed/25097802
http://dx.doi.org/10.4161/onci.28611
_version_ 1782480754258739200
author Madan, Ravi A
Heery, Christopher R
Gulley, James L
author_facet Madan, Ravi A
Heery, Christopher R
Gulley, James L
author_sort Madan, Ravi A
collection PubMed
description Prostvac is a poxviral-based vaccine designed to target prostate-specific antigen (PSA) in prostate cancer patients. Recently, the potential toxicity and immunological impact of this immunotherapy were reviewed in the context of new clinical data. Our findings suggest that Prostvac is safe and elicits anticancer immune responses, both alone and in combinatorial approaches.
format Online
Article
Text
id pubmed-4091323
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-40913232014-08-05 Poxviral-based vaccine elicits immunologic responses in prostate cancer patients Madan, Ravi A Heery, Christopher R Gulley, James L Oncoimmunology Author's View Prostvac is a poxviral-based vaccine designed to target prostate-specific antigen (PSA) in prostate cancer patients. Recently, the potential toxicity and immunological impact of this immunotherapy were reviewed in the context of new clinical data. Our findings suggest that Prostvac is safe and elicits anticancer immune responses, both alone and in combinatorial approaches. Landes Bioscience 2014-04-29 /pmc/articles/PMC4091323/ /pubmed/25097802 http://dx.doi.org/10.4161/onci.28611 Text en Copyright © 2014 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Madan, Ravi A
Heery, Christopher R
Gulley, James L
Poxviral-based vaccine elicits immunologic responses in prostate cancer patients
title Poxviral-based vaccine elicits immunologic responses in prostate cancer patients
title_full Poxviral-based vaccine elicits immunologic responses in prostate cancer patients
title_fullStr Poxviral-based vaccine elicits immunologic responses in prostate cancer patients
title_full_unstemmed Poxviral-based vaccine elicits immunologic responses in prostate cancer patients
title_short Poxviral-based vaccine elicits immunologic responses in prostate cancer patients
title_sort poxviral-based vaccine elicits immunologic responses in prostate cancer patients
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4091323/
https://www.ncbi.nlm.nih.gov/pubmed/25097802
http://dx.doi.org/10.4161/onci.28611
work_keys_str_mv AT madanravia poxviralbasedvaccineelicitsimmunologicresponsesinprostatecancerpatients
AT heerychristopherr poxviralbasedvaccineelicitsimmunologicresponsesinprostatecancerpatients
AT gulleyjamesl poxviralbasedvaccineelicitsimmunologicresponsesinprostatecancerpatients

Ejemplares similares